Portage Biotech is a clinical stage immune-oncology company focused on overcoming immune resistance. Co. sources, nurtures and develops therapies for a variety of cancers, by funding, implementing product development strategies, clinical counsel/trial design, shared services, financial and project management to enable execution of commercially informed development plans. Co.'s drug development pipeline portfolio encompasses products or technologies based on biology addressing known resistance pathways/mechanisms of check point inhibitors with scientific rationales, including intratumoral delivery, nanoparticles, liposomes, aptamers, and virus-like particles. The PRTG stock yearly return is shown above.
The yearly return on the PRTG stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the PRTG annual return calculation with any dividends reinvested as applicable (on ex-dates).
|